“The Retinopathy of Prematurity market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2022-2032). Furthermore, launching various multiple- Retinopathy of Prematurity pipeline products will significantly revolutionize the Retinopathy of Prematurity market dynamics”
The Retinopathy of Prematurity market report provides current treatment practices, Retinopathy of Prematurity emerging drugs, Retinopathy of Prematurity market share of individual therapies, and current and forecasted epidemiology in 7MM covering the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032. Retinopathy of Prematurity Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed Retinopathy of Prematurity clinical trials profiles, key cross-competition, launch date along with product development activities.
Key Takeaways from the Retinopathy of Prematurity Market Report
- The increase in Retinopathy of Prematurity market size is a direct consequence of expected approval of emerging therapies and increasing cases of Retinopathy of Prematurity (ROP) in the 7MM.
- According According to the Freitas et al. 2018, the incidence of ROP at any stage was 33.9% while the incidence of type 1 prethreshold ROP was 5.0%.
- The leading Retinopathy Of Prematurity Companies include Bayer, Regeneron Pharmaceuticals, Novartis Pharmaceuticals, Elgan Pharma and others
- Promising Retinopathy of Prematurity Pipeline Therapies include Ranibizumab, Aflibercept, ELGN-EYE, and others
Discover more about therapies set to grab major Retinopathy of Prematurity Market Share @ Retinopathy of Prematurity Market Size
Retinopathy of Prematurity Overview
Retinopathy of prematurity (ROP) is a disease of retinal vascular and capillary proliferation affecting premature infants undergoing oxygen therapy. Oxygen treatment results in pathologic growth of vessels in the developing retina that may lead to permanent damage to the retina as well as retinal detachment and macular folds.
Retinopathy of Prematurity Epidemiology Segmentation in the 7MM
- Total Retinopathy of Prematurity Incident Cases
- Retinopathy of Prematurity Severity-Specific Incident Cases
- Retinopathy of Prematurity Gestation Age-Specific Incident Cases
- Total Retinopathy of Prematurity Treated Cases
Download the report to understand which factors are driving Retinopathy of Prematurity Epidemiology Trends @ Retinopathy of Prematurity Epidemiological Insights
Recent Developmental Activities in the Retinopathy of Prematurity Treatment Landscape
- In February 2023, the US FDA approves Regeneron’s Eylea for retinopathy of prematurity in preterm infants. Eylea has been designed to block new blood vessels growth and reduce the ability of fluid flow through blood vessels in the eye by blocking VEGF-A and placental growth factor (PLGF) that are involved in ocular angiogenesis.
- ELGN-EYE is a formulation which is being developed by Elgan Pharma. It is recombinant human insulin that contains the same compounds present in amniotic fluid during pregnancy. The drug is in phase II for the treatment of pre-term infants ROP. The therapeutic goal is to promote the growth of retinal blood vessels, reduce the oxidative stress, and reduce inflammation.
Retinopathy of Prematurity Treatment Market
Retinopathy of Prematurity Treatment depends on the stage and severity of the condition. The milder stages of the disease typically resolve by themselves, and do not require treatment. However, if the disease has progressed to a point where baby’s vision is at risk, treatment is needed. The goal of treatment is to reduce the risk of baby’s retina detaching, which can severely impact vision. There is a greater understanding in the diagnosis and treatment of ROP and its response to treatment. The advent of anti-VEGF therapy has provided ROP providers with a treatment modality that may lead to improved visual outcomes without the need for peripheral retinal ablation.
Retinopathy of Prematurity Market Dynamics
The Retinopathy of Prematurity market dynamics is anticipated to change in the coming years owing to the emerging pipeline and the rise in number of healthcare spending with the rise of awareness across the world. Key player, such as Elgan Pharma is involved in developing therapy for Retinopathy of Prematurity (ROP).
Learn more about the Retinopathy of Prematurity Pipeline Therapies in clinical trials @ Retinopathy of Prematurity Market Landscape
Scope of the Retinopathy of Prematurity Market Report
- Coverage- 7MM
- Study Period- 2019-2032
- Forecast Period- 2022-2032
- Retinopathy of Prematurity Companies- Bayer (NYSE: BAYRY), Regeneron Pharmaceuticals (NYSE: REGN), Novartis Pharmaceuticals (NYSE: NVS), Elgan Pharma and others
- Retinopathy of Prematurity Pipeline Therapies- Ranibizumab, Aflibercept, ELGN-EYE, and others.
- Retinopathy of Prematurity Market Dynamics: Retinopathy of Prematurity Market Drivers and Barriers
- Retinopathy of Prematurity Market Access and Reimbursement, Unmet Needs, and Emerging Drugs
Discover more about Retinopathy of Prematurity Drugs in development @ Retinopathy of Prematurity Ongoing Clinical Trials Analysis
Table of Content
- Key Insights
- Executive Summary of Retinopathy of Prematurity
- Competitive Intelligence Analysis for Retinopathy of Prematurity
- Retinopathy of Prematurity: Market Overview at a Glance
- Retinopathy of Prematurity: Disease Background and Overview
- Patient Journey
- Retinopathy of Prematurity Epidemiology and Patient Population
- Retinopathy of Prematurity Treatment Algorithm, Current Treatment, and Medical Practices
- Retinopathy of Prematurity Unmet Needs
- Key Endpoints of Retinopathy of Prematurity Treatment
- Retinopathy of Prematurity Marketed Products
- Retinopathy of Prematurity Emerging Therapies
- Retinopathy of Prematurity: Seven Major Market Analysis
- Attribute analysis
- 7MM: Market Outlook
- Access and Reimbursement Overview of Retinopathy of Prematurity
- KOL Views
- Retinopathy of Prematurity Market Drivers
- Retinopathy of Prematurity Market Barriers
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Get in touch with our Business executive @ Retinopathy of Prematurity Market Drivers and Barriers
List of Trending Market Research Reports in 2023
Allergic Contact Dermatitis Market | Angio Suites Market | Angiofibroma Market | B Cell Chronic Lymphocytic Leukemia Market | Chagas Disease Market | Cone Rod Dystrophy Market | Dyspepsia Market | Erosive Hand Osteoarthritis Market | Exocrine Pancreatic Insufficiency Market | Gastroparesis Market |Graves’ Disease Market | Pediatric Growth Hormone Deficiency PGHD Market | Pelvic Organ Prolapse Market | Peripheral Nerve Repair Devices Market | Peripheral Vascular Devices Market | Perivascular Epithelioid Cell Tumor Market | Pleural Effusion Market | Polycystic Ovarian Syndrome Market | Pork Tapeworm Infection/Neurocysticercosis Market | Positive Airway Pressure Device Market | Progressive Supranuclear Palsy Market | Propionic Acidemia Market | Psoriasis Vulgaris Market | Radiation-induced Esophagitis Market | Radiotherapy Induced Oral Mucositis Market | Reactive Airway Disease Market | Schistosomiasis Market | Secondary Progressive Multiple Sclerosis SPMS Market | Skin Neoplasms Market | Smoking Cessation and Nicotine Addiction Market | Stem Cell Market | Supraventricular Tachycardia Market | Surgical Sealant Tissue Patch Market | Surgical Site Infections Market | Synovial Sarcoma Market | Tardive Dyskinesia Market | Tay-Sachs Disease Market | Transcatheter Treatment Market | Transthyretin Amyloidosis Market | Trichomoniasis- Market | Tropical Spastic Paraparesis Market | Tuberculosis Market | Uveitis Market | Wolman Disease Market | X-Linked Retinitis Pigmentosa Market | Familial Primary Pulmonary Hypertension Market | Astigmatism Market | Neurostimulation Devices Market | Opioid Induced Constipation Market | Nonalcoholic Steatohepatitis Market | Meningioma Market | Pediatric Growth Hormone Deficiency Pghd Market | Progressive Multifocal Leukoencephalopathy Market | Osteoarthritis Market | Actinic Keratosis Market | Blood Gas And Electrolyte Analyzers Market | Cerebral Aneurysm Market | Neurovascular Devices Market | Capnography Device Market | Acute Coronary Syndrome Market
Read More about Consulting Services:
Biotech Consulting | Business Consulting Services | Consulting Services | Healthcare Business Development | Healthcare Consulting Services | Healthcare Strategy Consulting | Life Science Consulting | Life Science Consulting Firms
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj